Title: Financial News - LegoChem sings contract with Fosun Pharma to export ADC technology 

Publication: Financial News/ Seuk Geun Hong

Date: 18 August 2015

Summary

• LegoChem Biosciences signed a licensing-out contract with Fosun Pharma to transfer technology to develop and commercialize ADC.

• LegoChem's ADC technology is highly acclaimed to be innovative for its improved drug stability in blood.

• Fosun Pharma will proceed in clinical development, approval, production, and commercialization stages of ADC in the Greater China region.

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).